Also Announces FDA approval to begin first in Human Adenoviral Vaccine  Trials for Patients with Her 2 positive Breast Cancer, another Cancer Moonshot 2020 milestone

 CULVER CITY, Calif. – May 10, 2016 – Dr. Patrick Soon-Shiong CEO of NantWorks and founder of Cancer Moonshot 2020, today announced that a novel genetically engineered adenovirus vaccine designed to treat colon cancer showed, in Phase II testing, a more than doubling of survival rate, with little to no toxicity, with some patients alive now more than five years after receiving the colon vaccine while on no other therapy. Dr. Soon-Shiong said that the vaccine which treated more than 30 patients with metastatic colon cancer, who had failed over 5 rounds of chemotherapy and had an overall life expectancy of 4.5 months, showed what he believed to be very promising and exciting results.

He told attendees that the novel vaccine, a genetically engineered common cold virus (Adenovirus) armed with the unique biological signature of the patient’s tumor antigen (CEA), is injected under the skin like a flu shot to find and direct the dendritic cell to activate the killer T-Cells, thus beginning to intelligently orchestrate the patient’s immune system to lead to lifelong immunity against the tumor cell. In this trial with patients who failed all standard forms of therapy and expected historical survival rate of less than 4.5 months, the median survival was more than doubled after receiving the vaccine.

“Cancer care is undergoing a paradigm shift from highly toxic, high dose chemotherapy to considerably less toxic immunotherapy,” said Dr. Soon-Shiong. “Through incredible advances in super-computing and next-generation bioinformatics, we can now rapidly unearth the tumor’s genetic makeup and unique properties. This makes feasible the development of patient-specific vaccines directed against individual tumor associated antigens, which reflect mutations in a patient’s tumor.”

Dr. Soon-Shiong said that with the promising results of the colon cancer vaccine, the FDA has now also approved the vaccine for trials with patients with her 2 positive breast cancer. This trial, supported by NantBio, will lead to studies including the very aggressive form of breast cancer known as triple-negative breast cancer (TNBC)


About Cancer MoonShot 2020

The Cancer MoonShot 2020 Program is one of the most comprehensive cancer collaborative initiative launched to date, seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. This initiative aims to explore a new paradigm in cancer care by initiating randomized Phase II trials in patients at all stages of disease in 20 tumor types in 20,000 patients within the next 36 months. These findings will inform Phase III trials and the aspirational moonshot to develop an effective vaccine-based immunotherapy to combat cancer by 2020. For more information, please visit and follow Cancer MoonShot 2020 on Twitter

About NantWorks

NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operate at the nexus of innovation and infrastructure.

The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically -informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please visit and follow Dr. Soon-Shiong on Twitter @Dr.PatSoonShiong.